Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib, TQB2450, and SOX as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression
NCT06939452Phase 2Active, not recruiting
- Start
- Jun 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and benmelstobart in gastric cancer (GC) and gastroesophageal junction adenocarcinoma. Primary endpoint: Objective Response Rate at 2 years. Started Jun 2023; status: active, not recruiting.
02
Drugs
anlotinibbenmelstobart
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06939452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06939452.